Education
About Us
Working with TipRanks
Follow Us
BrightPath Biotherapeutics Co.Ltd. (JP:4594)
:4594
RESEARCH TOOLSreports
See the Price Targets and Ratings of:
4594 Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
¥77
Hold
2.67%
Upside
Reiterated
08/02/25
BrightPath Biotherapeutics' overall stock score is driven by technical analysis indicating positive momentum, despite significant financial challenges. The company's strong equity base and low leverage offer some support, but persistent losses and negative cash flow raise sustainability concerns. The negative P/E ratio and lack of dividend yield further detract from its attractiveness as a valuation play.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
¥77
Hold
2.67%
Upside
Reiterated
08/02/25
BrightPath Biotherapeutics' overall stock score is driven by technical analysis indicating positive momentum, despite significant financial challenges. The company's strong equity base and low leverage offer some support, but persistent losses and negative cash flow raise sustainability concerns. The negative P/E ratio and lack of dividend yield further detract from its attractiveness as a valuation play.
4594 Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Strong Buy
0
0
0
Buy
0
0
0
Hold
1
8
11
Sell
0
1
1
Strong Sell
0
0
0
total
1
9
12
Each month's total comprises the sum of three months' worth of ratings.
4594 Stock Forecast FAQ
What is JP:4594’s average 12-month price target, according to analysts?
Based on analyst ratings, BrightPath Biotherapeutics Co.Ltd.’s 12-month average price target is 49.00.
What is JP:4594’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for JP:4594, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BrightPath Biotherapeutics Co.Ltd. a Buy, Sell or Hold?
BrightPath Biotherapeutics Co.Ltd. has a consensus rating of Hold, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is BrightPath Biotherapeutics Co.Ltd.’s share price target?
The average share price target for BrightPath Biotherapeutics Co.Ltd. is 49.00. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ¥49.00 ,and the lowest forecast is ¥49.00. The average share price target represents -34.67% Decrease from the current price of ¥75.
The highest analyst share price target is ¥49.00 ,and the lowest forecast is ¥49.00. The average share price target represents -34.67% Decrease from the current price of ¥75.
What do analysts say about BrightPath Biotherapeutics Co.Ltd.?
BrightPath Biotherapeutics Co.Ltd.’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of BrightPath Biotherapeutics Co.Ltd.?
To buy shares of JP:4594, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.